JP2013032308A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013032308A5 JP2013032308A5 JP2011169082A JP2011169082A JP2013032308A5 JP 2013032308 A5 JP2013032308 A5 JP 2013032308A5 JP 2011169082 A JP2011169082 A JP 2011169082A JP 2011169082 A JP2011169082 A JP 2011169082A JP 2013032308 A5 JP2013032308 A5 JP 2013032308A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- dry powder
- depression
- earthworm dry
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 241000361919 Metaphire sieboldi Species 0.000 claims 3
- 239000000843 powder Substances 0.000 claims 3
- 239000004480 active ingredient Substances 0.000 claims 2
- 239000000935 antidepressant agent Substances 0.000 claims 2
- 229940005513 antidepressants Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229960004341 escitalopram Drugs 0.000 claims 2
- WSEQXVZVJXJVFP-FQEVSTJZSA-N escitalopram Chemical compound C1([C@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-FQEVSTJZSA-N 0.000 claims 2
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 claims 1
- WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 claims 1
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 claims 1
- GDLIGKIOYRNHDA-UHFFFAOYSA-N Clomipramine Chemical compound C1CC2=CC=C(Cl)C=C2N(CCCN(C)C)C2=CC=CC=C21 GDLIGKIOYRNHDA-UHFFFAOYSA-N 0.000 claims 1
- UEQUQVLFIPOEMF-UHFFFAOYSA-N Mianserin Chemical compound C1C2=CC=CC=C2N2CCN(C)CC2C2=CC=CC=C21 UEQUQVLFIPOEMF-UHFFFAOYSA-N 0.000 claims 1
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 claims 1
- 229960002519 amoxapine Drugs 0.000 claims 1
- QWGDMFLQWFTERH-UHFFFAOYSA-N amoxapine Chemical compound C12=CC(Cl)=CC=C2OC2=CC=CC=C2N=C1N1CCNCC1 QWGDMFLQWFTERH-UHFFFAOYSA-N 0.000 claims 1
- 229960001653 citalopram Drugs 0.000 claims 1
- 229960004606 clomipramine Drugs 0.000 claims 1
- -1 dresspin Chemical compound 0.000 claims 1
- 229960002464 fluoxetine Drugs 0.000 claims 1
- 229960004038 fluvoxamine Drugs 0.000 claims 1
- CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 claims 1
- 229960004801 imipramine Drugs 0.000 claims 1
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 claims 1
- 229960002813 lofepramine Drugs 0.000 claims 1
- SAPNXPWPAUFAJU-UHFFFAOYSA-N lofepramine Chemical compound C12=CC=CC=C2CCC2=CC=CC=C2N1CCCN(C)CC(=O)C1=CC=C(Cl)C=C1 SAPNXPWPAUFAJU-UHFFFAOYSA-N 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229960004090 maprotiline Drugs 0.000 claims 1
- QSLMDECMDJKHMQ-GSXCWMCISA-N maprotiline Chemical compound C12=CC=CC=C2[C@@]2(CCCNC)C3=CC=CC=C3[C@@H]1CC2 QSLMDECMDJKHMQ-GSXCWMCISA-N 0.000 claims 1
- 229960003955 mianserin Drugs 0.000 claims 1
- 229960001785 mirtazapine Drugs 0.000 claims 1
- RONZAEMNMFQXRA-UHFFFAOYSA-N mirtazapine Chemical compound C1C2=CC=CN=C2N2CCN(C)CC2C2=CC=CC=C21 RONZAEMNMFQXRA-UHFFFAOYSA-N 0.000 claims 1
- 229960001800 nefazodone Drugs 0.000 claims 1
- VRBKIVRKKCLPHA-UHFFFAOYSA-N nefazodone Chemical compound O=C1N(CCOC=2C=CC=CC=2)C(CC)=NN1CCCN(CC1)CCN1C1=CC=CC(Cl)=C1 VRBKIVRKKCLPHA-UHFFFAOYSA-N 0.000 claims 1
- 229960002296 paroxetine Drugs 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 229960002073 sertraline Drugs 0.000 claims 1
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 claims 1
- 229960002431 trimipramine Drugs 0.000 claims 1
- ZSCDBOWYZJWBIY-UHFFFAOYSA-N trimipramine Chemical compound C1CC2=CC=CC=C2N(CC(CN(C)C)C)C2=CC=CC=C21 ZSCDBOWYZJWBIY-UHFFFAOYSA-N 0.000 claims 1
- 229960004688 venlafaxine Drugs 0.000 claims 1
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2011169082A JP5856725B2 (ja) | 2011-08-02 | 2011-08-02 | うつ病治療用または予防用医薬組成物 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2011169082A JP5856725B2 (ja) | 2011-08-02 | 2011-08-02 | うつ病治療用または予防用医薬組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013032308A JP2013032308A (ja) | 2013-02-14 |
| JP2013032308A5 true JP2013032308A5 (enExample) | 2014-09-04 |
| JP5856725B2 JP5856725B2 (ja) | 2016-02-10 |
Family
ID=47788495
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011169082A Active JP5856725B2 (ja) | 2011-08-02 | 2011-08-02 | うつ病治療用または予防用医薬組成物 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP5856725B2 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3091974B1 (en) | 2014-01-06 | 2020-04-01 | Shield TX (UK) Limited | Dosage regimen of ferric trimaltol |
| EP3097918B1 (en) * | 2014-01-20 | 2019-04-03 | Well Stone Co. | Catecholamine production accelerator, and therapeutic and preventive agent and therapeutic and preventive food composition for diseases caused by catecholamine deficiency |
| GB201418710D0 (en) | 2014-10-21 | 2014-12-03 | Iron Therapeutics Holdings Ag | Dosage regimen |
| JP6321521B2 (ja) * | 2014-11-04 | 2018-05-09 | Ｗｅｌｌ Ｓｔｏｎｅ 有限会社 | タウ蛋白産生促進剤、タウ蛋白の欠乏に起因する疾患の治療薬・予防薬および治療用・予防用食品組成物 |
| RU2696782C1 (ru) * | 2018-02-27 | 2019-08-06 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Ставропольский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО СтГМУ Минздрава России) | Способ купирования резистентных депрессивных синдромов психосоматического круга |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004292402A (ja) * | 2003-03-28 | 2004-10-21 | Mihara Lr Kenkyusho:Kk | ミミズ乾燥粉末の製造方法 |
| JP2007153802A (ja) * | 2005-12-05 | 2007-06-21 | Fujibio Co Ltd | 線溶活性を有するミミズ乾燥粉末及びその製造方法 |
| AU2008248382B2 (en) * | 2007-05-07 | 2013-07-18 | Chelsea Therapeutics, Inc. | Droxidopa and pharmaceutical composition thereof for the treatment of mood disorders, sleep disorders, or attention deficit disorders |
-
2011
- 2011-08-02 JP JP2011169082A patent/JP5856725B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014198723A5 (enExample) | ||
| EP2444072A3 (en) | Non-mucoadhesive film dosage forms | |
| EA201491060A1 (ru) | Новые производные трифторметилоксадиазола и их применение для лечения заболевания | |
| JP2015515985A5 (enExample) | ||
| JP2017506624A5 (enExample) | ||
| JP2013032308A5 (enExample) | ||
| JP2016530291A5 (enExample) | ||
| JP2019535760A5 (ja) | ガボキサドールを用いた注意欠陥多動性障害（ａｄｈｄ）の治療方法 | |
| JP2018521007A5 (enExample) | ||
| JP2013536837A5 (enExample) | ||
| JP2014507475A5 (enExample) | ||
| MX2008011020A (es) | Compuestos de receptor sigma. | |
| EA201071138A1 (ru) | Применение дронедарона для получения лекарственного средства для лечения пациентов с аритмией и с повышенным уровнем креатинина в результате введения дронедарона | |
| JP2008266291A5 (enExample) | ||
| JP2009505991A5 (enExample) | ||
| WO2012111011A3 (en) | Low dosage combinations of fluoxetine and reboxetine for treating obesity | |
| UA108980C2 (en) | APPLICATION OF DONEDARONE FOR THE PREVENTION OF CARDIOVASCULAR HOSPITALIZATIONS | |
| JP2018505901A5 (enExample) | ||
| JP2016540799A5 (enExample) | ||
| BRPI0602397C1 (pt) | composições farmacêuticas para o tratamento das doenças gordurosas do fìgado, obesidade e demais doenças associadas à sìndrome metabólica e métodos de tratamento utilizando-se as referidas composições | |
| JP2012097034A5 (enExample) | ||
| RU2013127794A (ru) | Фармацевтическая комбинация и композиция для лечения ожирения и ее применение | |
| BR112012020415A2 (pt) | composição farmacêutica para a prevenção ou tratamento da osteoartrite | |
| WO2010098625A2 (ko) | 약제학적 제제 | |
| JP2017052778A5 (enExample) |